The rising incidence of inflammatory bowel diseases such as Crohn?s disease (CD) has become a global health care issue in the 21st century. The complex genetic underpinning is increasingly appreciated, while environmental cues and...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
FLAMINCO
Therapeutic discovery for Inflammatory Bowel Disease
150K€
Cerrado
PID2021-123918OB-I00
ESTUDIO DE LA HETEROGENIDAD EN LA ENFERMEDAD INFLAMATORIA IN...
339K€
Cerrado
SAF2016-80072-P
MODULACION DE LA FIBROSIS INTESTINAL POR EL SISTEMA INMUNE I...
121K€
Cerrado
PID2019-108996RB-I00
RELEVANCIA FUNCIONAL DE LA FIRMA MOLECULAR EN LAS COMPLICACI...
157K€
Cerrado
RTI2018-101586-A-I00
CONTROL PRECISO DE LA NATURALEZA DE LA AUTOFAGIA EN LA HOMEO...
157K€
Cerrado
INTERCONNECTIONS
Interplay of epithelial mechanics and neutrophil activation...
174K€
Cerrado
Información proyecto MEGI CD
Duración del proyecto: 60 meses
Fecha Inicio: 2022-03-08
Fecha Fin: 2027-03-31
Descripción del proyecto
The rising incidence of inflammatory bowel diseases such as Crohn?s disease (CD) has become a global health care issue in the 21st century. The complex genetic underpinning is increasingly appreciated, while environmental cues and specifically a Western diet are suspected to impact development and course of disease. Mechanistic insights that would support this assumption remain scarce and specific nutrients that trigger a flare are unknown. Westernisation of dietary habits is partly characterised by enrichment of long-chain fatty acids, which fuel metabolic inflammation of tissues beyond the gut. Here, we propose to establish the concept of metabolic gut inflammation as a fuel for CD. By analysing transgenic mice, human CD organoids and two independent CD patient cohorts, we seek to establish how dietary polyunsaturated fatty acids (PUFAs) affect gut inflammation and disease course. The proposed work is based on our previous observations that dietary PUFAs trigger a chemokine response and Crohn?s-like enteritis in mice, which is restricted by intestinal epithelial Glutathione peroxidase 4 (GPX4). GPX4 is an evolutionary conserved anti-oxidative enzyme which shows impaired activity in CD epithelium. The proposed work will identify how dietary PUFAs elicit gut inflammation in mice and which epithelial lineage executes the inflammatory response. In a next step, I propose to establish a critical crosstalk between GPX4 and metabolic hubs in gut epithelium to provide a basis for the concept of metabolic gut inflammation. Finally, we seek to translate findings by establishing that PUFAs evoke an inflammatory response from CD epithelium, and that PUFA intake impacts disease course. MEGI CD comprehends basic and translational science to set the basis for novel therapeutic strategies in a complex illness that requires better treatment modalities. The study will prove the concept of metabolic gut inflammation as a major driver of human CD, a basis for nutritional therapy.